Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanism and early clinical trial reports without systematic review or meta-analysis.
PubMed 23546520 · doi:10.1038/nrclinonc.2013.46
What was done
This narrative review summarizes the biological principles, development, and early clinical trial findings of adoptive transfer therapies using genetically engineered anti-CD19 chimeric antigen receptor (CAR) T cells for advanced B-cell malignancies.
What was found
The abstract reports no numerical data. It notes that following an initial 2010 report of partial remission and normal B-cell eradication in a lymphoma patient, subsequent patients with advanced B-cell malignancies achieved long-term remissions. Treatment also resulted in the persistent elimination of normal CD19-positive B cells and acute adverse effects linked to elevated serum inflammatory cytokines.
Why it matters
It documents the emergence of CD19-targeted CAR T-cell therapy as a viable immunotherapeutic approach capable of inducing durable responses in treatment-refractory B-cell cancers.
Limits
The abstract describes early-phase non-randomized data without specifying sample sizes, objective response rates, survival metrics, or follow-up duration, and long-term safety remained incompletely characterized.
Cited by
- supports CD19 is expressed on the surface of normal healthy B cells as well as multiple types of B-cell leukemias and lymphomas.